Global Radioimmunotherapy Market, Dosage, Price & Clinical Pipeline Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global Radioimmunotherapy Market, Dosage, Price & Clinical Pipeline Outlook 2022” Report Highlights:
Out of all the existing cancer therapeutics being researched upon, immunotherapy is being anticipated as the most promising and viable segment of modern cancer therapeutics. Cancer Immunotherapy is the use of the body’s own immune system to treat cancer. Years of research has proved that the immune system can be trained to identify and eliminate particular cells from the body by giving suitable cues. This unique property of the immune system has widely been utilized to treat diseases by modulating immune responses.
It was however observed that the efficacy of cancer therapy significantly improved when combined with traditional radiation therapy which then gave rise to a new class of cancer therapy known as the cancer Radioimmunotherapy. The amalgamation of radiation therapy with immunotherapy proved to be a breakthrough method of cancer therapy with impressive results in cancers such as the Non- Hodgkin lymphoma; which was earlier considered to be a non-treatable cancer.
Ibritumomab tiuxetan and Iodine (131I) tositumomab are the two most popular Radio immunotherapeutics that received FDA Approval in the year 2002 and 2003 respectively. As of now only these two radio immunotherapeutics have been marketed globally for the treatment of Non Hodgkin lymphoma under the brand name Zevalin(Ibriumomab tiuxetan) and Bexxar(Tositumomab).
The excellent results obtained in cancer Radioimmunotherapy in the past & current research has led to the segment progressing rapidly in terms of both clinical and commercial aspects with increased attention from pharmaceutical and healthcare sectors around the world. While it has already been approved as a standard treatment for Non Hodgkin Lymphoma and follicular lymphoma, it has yet to prove its clinical efficacy in other cancer types.
An insight into the clinical pipeline and current status of all the cancer types associated with Radioimmunotherapy presents an optimistic picture regarding its improvement with efficacy. With the advancement in science and technology, the Radioimmunotherapy segment is bound to progress at a rapid rate thus making it a promising cancer therapeutic of the future.
KuicK Research report on global Radioimmunotherapy aims at providing an in-depth analysis of the market with special emphasis on the Global market size, current market trend and factors affecting the future market growth. Additionally the report includes comparative price, dosage and therapy cost analysis of marketed Radioimmunotherapy drugs providing a detailed insight into the Radioimmunotherapy marketed products.
“Global Radioimmunotherapy Market, Dosage, Price & Clinical Pipeline Outlook 2022” Report Highlights:
- Need & Efficacy of Radioimmunotherapy
- Components of Radioimmunotherapy
- Clinical Status of Radioimmunotherapy in Various Cancer Therapy
- Emerging Opportunities in the Radioimmunotherapy Segment
- Patent, Dosage & Price Analysis
- Antibodies in Radioimmunotherapy
- Global Radioimmunotherapy Clinical Pipeline: 68 Drugs
- Clinical Pipeline analysis by Phase
Out of all the existing cancer therapeutics being researched upon, immunotherapy is being anticipated as the most promising and viable segment of modern cancer therapeutics. Cancer Immunotherapy is the use of the body’s own immune system to treat cancer. Years of research has proved that the immune system can be trained to identify and eliminate particular cells from the body by giving suitable cues. This unique property of the immune system has widely been utilized to treat diseases by modulating immune responses.
It was however observed that the efficacy of cancer therapy significantly improved when combined with traditional radiation therapy which then gave rise to a new class of cancer therapy known as the cancer Radioimmunotherapy. The amalgamation of radiation therapy with immunotherapy proved to be a breakthrough method of cancer therapy with impressive results in cancers such as the Non- Hodgkin lymphoma; which was earlier considered to be a non-treatable cancer.
Ibritumomab tiuxetan and Iodine (131I) tositumomab are the two most popular Radio immunotherapeutics that received FDA Approval in the year 2002 and 2003 respectively. As of now only these two radio immunotherapeutics have been marketed globally for the treatment of Non Hodgkin lymphoma under the brand name Zevalin(Ibriumomab tiuxetan) and Bexxar(Tositumomab).
The excellent results obtained in cancer Radioimmunotherapy in the past & current research has led to the segment progressing rapidly in terms of both clinical and commercial aspects with increased attention from pharmaceutical and healthcare sectors around the world. While it has already been approved as a standard treatment for Non Hodgkin Lymphoma and follicular lymphoma, it has yet to prove its clinical efficacy in other cancer types.
An insight into the clinical pipeline and current status of all the cancer types associated with Radioimmunotherapy presents an optimistic picture regarding its improvement with efficacy. With the advancement in science and technology, the Radioimmunotherapy segment is bound to progress at a rapid rate thus making it a promising cancer therapeutic of the future.
KuicK Research report on global Radioimmunotherapy aims at providing an in-depth analysis of the market with special emphasis on the Global market size, current market trend and factors affecting the future market growth. Additionally the report includes comparative price, dosage and therapy cost analysis of marketed Radioimmunotherapy drugs providing a detailed insight into the Radioimmunotherapy marketed products.
1. CANCER RADIOIMMUNOTHERAPY - AMALGAMATION THERAPY FOR ELEVATED EFFICACY
1.1 Prologue to Cancer Radioimmunotherapy
1.2 History & Evolution of Cancer Radioimmunotherapy
2. RADIOIMMUNOTHERAPY - AN INSIGHT INTO ITS NEED & EFFICACY
2.1 High Unmet Medical Needs & Failure of Conventional Cancer Therapeutics
2.2 Targeted Therapy for Higher Efficacy
2.3 Superiority of Radioimmunotherapy over Other Cancer Therapeutics
3. FEATURES OF RADIOIMMUNOTHERAPY
3.1 Approved Benefits Associated with Radioimmunotherapy
3.2 Radioimmunotherapy using Monoclonal Antibodies
4. COMPONENTS OF RADIOIMMUNOTHERAPY
4.1 Tumor Antigens - Potential Targets for Monoclonal Antibodies
4.2 Radionuclides
4.3 Antibodies - Key Components in Radioimmunotherapy
5. RADIOIMMUNOTHERAPY - PRINCIPLE & ACTION
6. CLINICAL STATUS OF RADIOIMMUNOTHERAPY IN VARIOUS CANCER THERAPY
6.1 Non Hodgkin Lymphoma (NHL)
6.2 Follicular Lymphoma
6.3 Solid Tumors
6.4 Breast Cancer
6.5 Ovarian Cancer
6.6 Osteosarcoma
6.7 Neuroblastoma
6.8 Prostate Cancer
7. EMERGING OPPORTUNITIES & AVENUES IN THE RADIOIMMUNOTHERAPY SEGMENT
7.1 Immune Checkpoint Inhibitors & Radioactive Iodine in Cancer Radioimmunotherapy
7.2 Nanotechnologically Created Radiotracer: For Efficient Delivery of Radioactivity in Tumor Cells
8. RADIOIMMUNOTHERAPY MARKET - DOSAGE & PRICE ANALYSIS OF MONOCLONAL ANTIBODIES INVOLVED
8.1 Ibritumomab tiuxetan (Zevalin) & Rituxan– Dosage & Price Analysis in Follicular B-cell Non-Hodgkin Lymphoma
8.2 Zevalin & Rituxan: Therapy Cost Analysis
8.3 Comparative Cost Analysis of Radioimmunotherapy with Traditional Cancer therapy Methods
8.4 Tositumomab and iodine I 131 Tositumomab (Bexxar)
9. MARKET PERFORMANCE & TRENDS IN RADIOIMMUNOTHERAPEUTICS SEGMENT
9.1 Better Safety & Efficacy but Limited Growth Opportunity
9.2 Decreasing Sales of Zevalin Threatening the Radioimmunotherapy Market
9.3 Involvement of Blockbuster Therapeutics in Radioimmunotherapy to Ensure Stability in the Future
9.4 Emerging Pattern of Radioimmunotherapy Drug Referrals
10. RADIOIMMUNOTHERAPY MONOCLONAL ANTIBODIES CURRENTLY UNDER DEVELOPMENT & THEIR MARKET POTENTIAL
10.1 Epratuzumab
10.2 Lintuzumab
10.3 Labetuzumab
10.4 Trastuzumab (Herceptin)
11. ANTIBODIES IN RADIOIMMUNOTHERAPY - PATENT ANALYSIS
12. REGIONAL ANALYSIS OF THE RADIOIMMUNOTHERAPY MARKET
12.1 North America
12.1.1 United States (US)
12.1.2 Canada
12.2 Europe
12.2.1 Germany
12.2.2 France
12.2.3 United Kingdom (UK)
12.2.4 Rest of Europe
12.3 Asia - Pacific
12.3.1 China & India
12.3.2 Japan
12.3.3 Australia
12.4 Rest of the World
13. GLOBAL RADIOIMMUNOTHERAPY MARKET DRIVING PARAMETERS
14. RADIOIMMUNOTHERAPY - OVERCOMING THE CHALLENGES & SHORTCOMINGS
15. FUTURE FORECAST & PERSPECTIVE REGARDING THE IMMUNOTHERAPY SEGMENT
15.1 Global Approval of Radioimmunotherapy to Enhance Market Growth in Future
15.2 Radiopharmaceutical Market & its Impact on the Radioimmunotherapy market growth
15.3 Other Market Propelling Factors
16. GLOBAL RADIOIMMUNOTHERAPY CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
16.1 Global Radiopharmaceuticals Pipeline Overview
16.2 Unknown
16.3 Research
16.4 Preclinical
16.5 Clinical
16.6 Phase-0
16.7 Phase-I
16.8 Phase-I/II
16.9 Phase-II
16.10 Phase-III
16.11 Preregistration
16.12 Registered
17. COMPETITIVE LANDSCAPE
17.1 Bayer Healthcare Pharmaceuticals
17.2 BioSynthema
17.3 Clarity Pharmaceuticals
17.4 Curasight
17.5 Endocyte
17.6 Immunomedics
17.7 Molecular Insight Pharmaceuticals
17.8 Nordic Nanovector
17.9 PDL Biopharma
17.10 Philogen
17.11 RadioMedix
17.12 Stella Pharma
17.13 Telix Pharmaceuticals
1.1 Prologue to Cancer Radioimmunotherapy
1.2 History & Evolution of Cancer Radioimmunotherapy
2. RADIOIMMUNOTHERAPY - AN INSIGHT INTO ITS NEED & EFFICACY
2.1 High Unmet Medical Needs & Failure of Conventional Cancer Therapeutics
2.2 Targeted Therapy for Higher Efficacy
2.3 Superiority of Radioimmunotherapy over Other Cancer Therapeutics
3. FEATURES OF RADIOIMMUNOTHERAPY
3.1 Approved Benefits Associated with Radioimmunotherapy
3.2 Radioimmunotherapy using Monoclonal Antibodies
4. COMPONENTS OF RADIOIMMUNOTHERAPY
4.1 Tumor Antigens - Potential Targets for Monoclonal Antibodies
4.2 Radionuclides
4.3 Antibodies - Key Components in Radioimmunotherapy
5. RADIOIMMUNOTHERAPY - PRINCIPLE & ACTION
6. CLINICAL STATUS OF RADIOIMMUNOTHERAPY IN VARIOUS CANCER THERAPY
6.1 Non Hodgkin Lymphoma (NHL)
6.2 Follicular Lymphoma
6.3 Solid Tumors
6.4 Breast Cancer
6.5 Ovarian Cancer
6.6 Osteosarcoma
6.7 Neuroblastoma
6.8 Prostate Cancer
7. EMERGING OPPORTUNITIES & AVENUES IN THE RADIOIMMUNOTHERAPY SEGMENT
7.1 Immune Checkpoint Inhibitors & Radioactive Iodine in Cancer Radioimmunotherapy
7.2 Nanotechnologically Created Radiotracer: For Efficient Delivery of Radioactivity in Tumor Cells
8. RADIOIMMUNOTHERAPY MARKET - DOSAGE & PRICE ANALYSIS OF MONOCLONAL ANTIBODIES INVOLVED
8.1 Ibritumomab tiuxetan (Zevalin) & Rituxan– Dosage & Price Analysis in Follicular B-cell Non-Hodgkin Lymphoma
8.2 Zevalin & Rituxan: Therapy Cost Analysis
8.3 Comparative Cost Analysis of Radioimmunotherapy with Traditional Cancer therapy Methods
8.4 Tositumomab and iodine I 131 Tositumomab (Bexxar)
9. MARKET PERFORMANCE & TRENDS IN RADIOIMMUNOTHERAPEUTICS SEGMENT
9.1 Better Safety & Efficacy but Limited Growth Opportunity
9.2 Decreasing Sales of Zevalin Threatening the Radioimmunotherapy Market
9.3 Involvement of Blockbuster Therapeutics in Radioimmunotherapy to Ensure Stability in the Future
9.4 Emerging Pattern of Radioimmunotherapy Drug Referrals
10. RADIOIMMUNOTHERAPY MONOCLONAL ANTIBODIES CURRENTLY UNDER DEVELOPMENT & THEIR MARKET POTENTIAL
10.1 Epratuzumab
10.2 Lintuzumab
10.3 Labetuzumab
10.4 Trastuzumab (Herceptin)
11. ANTIBODIES IN RADIOIMMUNOTHERAPY - PATENT ANALYSIS
12. REGIONAL ANALYSIS OF THE RADIOIMMUNOTHERAPY MARKET
12.1 North America
12.1.1 United States (US)
12.1.2 Canada
12.2 Europe
12.2.1 Germany
12.2.2 France
12.2.3 United Kingdom (UK)
12.2.4 Rest of Europe
12.3 Asia - Pacific
12.3.1 China & India
12.3.2 Japan
12.3.3 Australia
12.4 Rest of the World
13. GLOBAL RADIOIMMUNOTHERAPY MARKET DRIVING PARAMETERS
14. RADIOIMMUNOTHERAPY - OVERCOMING THE CHALLENGES & SHORTCOMINGS
15. FUTURE FORECAST & PERSPECTIVE REGARDING THE IMMUNOTHERAPY SEGMENT
15.1 Global Approval of Radioimmunotherapy to Enhance Market Growth in Future
15.2 Radiopharmaceutical Market & its Impact on the Radioimmunotherapy market growth
15.3 Other Market Propelling Factors
16. GLOBAL RADIOIMMUNOTHERAPY CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
16.1 Global Radiopharmaceuticals Pipeline Overview
16.2 Unknown
16.3 Research
16.4 Preclinical
16.5 Clinical
16.6 Phase-0
16.7 Phase-I
16.8 Phase-I/II
16.9 Phase-II
16.10 Phase-III
16.11 Preregistration
16.12 Registered
17. COMPETITIVE LANDSCAPE
17.1 Bayer Healthcare Pharmaceuticals
17.2 BioSynthema
17.3 Clarity Pharmaceuticals
17.4 Curasight
17.5 Endocyte
17.6 Immunomedics
17.7 Molecular Insight Pharmaceuticals
17.8 Nordic Nanovector
17.9 PDL Biopharma
17.10 Philogen
17.11 RadioMedix
17.12 Stella Pharma
17.13 Telix Pharmaceuticals
LIST OF FIGURES
Figure 1-1: Evolution of Radiopharmaceuticals & Radioimmunotherapy
Figure 2-1: Need for Radioimmunotherapy
Figure 4-1: Components or Radioimmunotherapy
Figure 4-2: Monoclonal Antibodies - Vital Target Sites in Immunotherapy
Figure 4-3: Antigen Target & Their Therapy Antibodies in Radioimmunotherapy
Figure 4-4: Development of a Radionuclide
Figure 4-5: Half Life of Various Radioimmunotherapy Nuclides
Figure 4-6: Tissue Penetration of Key Radionuclides Used in Immunotherapy (mm)
Figure 4-7: Monoclonal Antibody in Radioimmunotherapy
Figure 5-1: Fundamental Working Mechanism of Radioimmunotherapy
Figure 6-1: Global - Non Hodgkin Lymphoma Incidence & Mortality by Numbers, 2018
Figure 6-2: Clinical Efficacy- Rituximab v/s Zevalin Standalone Therapy (%)
Figure 6-3: Global - Ovarian Cancer Incidence (per 100,000 Females), 2018
Figure 7-1: Humanized Antibodies - High Efficacy due to decreased Immunogenecity
Figure 8-1: Zevalin - Overview of Dosage Schedule
Figure 8-2: Zevalin- Dosage (milliCurie/kg)
Figure 8-3: Zevalin - Cost Analysis (US$/ml), 2018
Figure 8-4: Rituxan - Dosage (mg/m2)
Figure 8-5: Rituxan - Cost Analysis (US$/ml), 2018
Figure 8-6: Dosage - Median Radiation Dosimetry(Y-90 Zevalin cGy /mCi)
Figure 8-7: Zevalin & Rituxan: Average Therapy Cost Analysis (US$), 2018
Figure 8-8: Comparative Cost Analysis: Radioimmunotherapy v/s Traditional Cancer Therapeutics
Figure 8-9: Overview - Ositumab Dosing Schedule in Non-Hodgkin Lymphoma
Figure 8-10: Tositumab & I 131 Tositumab- Dosage (mg/Session)
Figure 8-11: Radiation dosimetry in Bexaar Therapy
Figure 9-1: Global - Zevalin Sales by Year (US$ Million), 2013-2016
Figure 9-2: Global - Rituxan Market Size (%), 2018
Figure 9-3: Global- Rituxan Sales (US$ Billion), 2015 & 2016
Figure 9-4: Global – Tositumomab Referral Trend Analysis by Practice (%), 2018
Figure 11-1: Patent Status - Monoclonal Antibody in Radioimmunotherapy, 2018
Figure 12-1: Canada - Comparative Price Analysis, RIT v/s Non-RIT treatment Modality (US$), 2018
Figure 13-1: Driving Factors of the Radioimmunotherapy Segment
Figure 14-1: Challenging Aspects of the Radioimmunotherapy Market
Figure 15-1: Zevalin - Sales Future Forecast (US$ Million), 2016-2022
Figure 15-2:Rituxan - Future Sales Forecast (US$ Billion), 2016-2022
Figure 15-3: Probability of Radioimmunotherapy Market Growth (%), 2018
Figure 15-4: Global - Radioimmunotherapy Market Size by End User (%), 2018
Figure 16-1: Global - Radiopharmaceuticals Clinical Pipeline by Phase (%), 2018 till 2022
Figure 16-2: Global - Radiopharmaceuticals Clinical Pipeline by Phase (Number), 2018 till 2022
Figure 1-1: Evolution of Radiopharmaceuticals & Radioimmunotherapy
Figure 2-1: Need for Radioimmunotherapy
Figure 4-1: Components or Radioimmunotherapy
Figure 4-2: Monoclonal Antibodies - Vital Target Sites in Immunotherapy
Figure 4-3: Antigen Target & Their Therapy Antibodies in Radioimmunotherapy
Figure 4-4: Development of a Radionuclide
Figure 4-5: Half Life of Various Radioimmunotherapy Nuclides
Figure 4-6: Tissue Penetration of Key Radionuclides Used in Immunotherapy (mm)
Figure 4-7: Monoclonal Antibody in Radioimmunotherapy
Figure 5-1: Fundamental Working Mechanism of Radioimmunotherapy
Figure 6-1: Global - Non Hodgkin Lymphoma Incidence & Mortality by Numbers, 2018
Figure 6-2: Clinical Efficacy- Rituximab v/s Zevalin Standalone Therapy (%)
Figure 6-3: Global - Ovarian Cancer Incidence (per 100,000 Females), 2018
Figure 7-1: Humanized Antibodies - High Efficacy due to decreased Immunogenecity
Figure 8-1: Zevalin - Overview of Dosage Schedule
Figure 8-2: Zevalin- Dosage (milliCurie/kg)
Figure 8-3: Zevalin - Cost Analysis (US$/ml), 2018
Figure 8-4: Rituxan - Dosage (mg/m2)
Figure 8-5: Rituxan - Cost Analysis (US$/ml), 2018
Figure 8-6: Dosage - Median Radiation Dosimetry(Y-90 Zevalin cGy /mCi)
Figure 8-7: Zevalin & Rituxan: Average Therapy Cost Analysis (US$), 2018
Figure 8-8: Comparative Cost Analysis: Radioimmunotherapy v/s Traditional Cancer Therapeutics
Figure 8-9: Overview - Ositumab Dosing Schedule in Non-Hodgkin Lymphoma
Figure 8-10: Tositumab & I 131 Tositumab- Dosage (mg/Session)
Figure 8-11: Radiation dosimetry in Bexaar Therapy
Figure 9-1: Global - Zevalin Sales by Year (US$ Million), 2013-2016
Figure 9-2: Global - Rituxan Market Size (%), 2018
Figure 9-3: Global- Rituxan Sales (US$ Billion), 2015 & 2016
Figure 9-4: Global – Tositumomab Referral Trend Analysis by Practice (%), 2018
Figure 11-1: Patent Status - Monoclonal Antibody in Radioimmunotherapy, 2018
Figure 12-1: Canada - Comparative Price Analysis, RIT v/s Non-RIT treatment Modality (US$), 2018
Figure 13-1: Driving Factors of the Radioimmunotherapy Segment
Figure 14-1: Challenging Aspects of the Radioimmunotherapy Market
Figure 15-1: Zevalin - Sales Future Forecast (US$ Million), 2016-2022
Figure 15-2:Rituxan - Future Sales Forecast (US$ Billion), 2016-2022
Figure 15-3: Probability of Radioimmunotherapy Market Growth (%), 2018
Figure 15-4: Global - Radioimmunotherapy Market Size by End User (%), 2018
Figure 16-1: Global - Radiopharmaceuticals Clinical Pipeline by Phase (%), 2018 till 2022
Figure 16-2: Global - Radiopharmaceuticals Clinical Pipeline by Phase (Number), 2018 till 2022
